Home

Frank L Jr Jaksch

CIK 1437237 · EXECUTIVE CHAIRMAN OF BOARD · last filed 2026-06-26

Frank L Jr Jaksch is an EXECUTIVE CHAIRMAN OF BOARD who has filed 39 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing, for NAGE, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

39

Lifetime Open-Market Net

-$1.08M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NAGE Director — $3.08 — $0 2 2026-06-26
Niagen Bioscience, Inc. (CDXC) Delisted EXECUTIVE CHAIRMAN OF BOARD 2,356,392 $7.87 $18.54M -$1.08M 21 2024-12-13

Recent Filings

39 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 NAGE Grant (A) — $0 EDGAR
2025-06-25 NAGE Grant (A) — $0 EDGAR
2024-12-13 NAGE Notice (144) −37,161 -$230.0K EDGAR
2024-12-13 Niagen Bioscience, Inc. (CDXC) Delisted Mixed +12,840 -$47.0K EDGAR
2024-06-21 Niagen Bioscience, Inc. (CDXC) Delisted Grant (A) — $0 EDGAR
2023-06-16 Niagen Bioscience, Inc. (CDXC) Delisted Grant (A) — $0 EDGAR
2023-06-13 Niagen Bioscience, Inc. (CDXC) Delisted Buy (P) +7,000 $11.8K EDGAR
2022-02-22 Niagen Bioscience, Inc. (CDXC) Delisted Grant (A) — $0 EDGAR
2021-03-17 Niagen Bioscience, Inc. (CDXC) Delisted Grant (A) — $0 EDGAR
2020-12-11 Niagen Bioscience, Inc. (CDXC) Delisted Mixed +3,838 -$3.8K EDGAR
Showing 1–10 of 39
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.